Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04496362 · ClinicalTrials.gov registry record · Phase 4

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

A Phase 4 study of Respiratory Failure and ECMO, sponsored by Baylor Research Institute.

Active
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT04496362 is a Phase 4 study of Respiratory Failure and ECMO that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 100 participants, below the 4,521-participant average among 40 other Respiratory Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04496362, a Phase 4 study of Respiratory Failure and ECMO, is active but no longer recruiting, sponsored by Baylor Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.

Interventions

  • DRUG subcutaneous heparin anticoagulation

Study Locations (1)

Texas

  • Baylor Scott & White Health research institute - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-10-10
Est. Completion 2026-06
Phase Phase 4

Sponsor

Baylor Research Institute

180 total trials

What the Registry Record Tells You About NCT04496362

The ClinicalTrials.gov registry entry for NCT04496362 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,521-participant average among 40 other Respiratory Failure trials with a reported enrollment target (98% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Respiratory Failure appearing as the primary indexed condition, and to 1 intervention - of which subcutaneous heparin anticoagulation is the first listed.

NCT04496362 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04496362 about?

NCT04496362 is a clinical study titled "Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study". This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.

What is the current status of trial NCT04496362?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2018-10-10. Estimated completion is 2026-06.

What conditions does trial NCT04496362 study?

This clinical trial studies the following conditions: Respiratory Failure, ECMO, Heparin.

What interventions are being tested in trial NCT04496362?

The interventions under investigation include: subcutaneous heparin anticoagulation (DRUG).

Who is sponsoring clinical trial NCT04496362?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04496362 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Respiratory Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.